Paradigm Biopharmaceuticals (PAR AU): Fund Raising Amidst Pipeline Progress Raises Conviction
Paradigm Biopharmaceuticals has requested a trading halt pending an announcement in relation to a capital raising. Normal trading will resume on...
794 Views
Australian Biotech Companies Amid Talk of Likely Interest Rate Cut
RBA keeps interest rates steady at 4.35%, while economists predict possible cut to 4.10% in 4Q24. Australian biotech companies should be in focus...
367 Views
Paradigm Biopharma - Termination of coverage
Edison Investment Research is terminating coverage on Atlantis Japan Growth Fund (AJG), Paradigm Biopharma (PAR), The European Smaller Companies...
377 Views
Paradigm Biopharma - Q1 results recap iPPS progress in OA & MPS
Paradigm announced Q1 results (for the quarter ending 30 September) and a A$30m capital raise to potentially extend its cash runway through to mid...
470 Views
Paradigm Biopharma - Disease modifying properties in iPPS Phase II
Paradigm reported favourable quantitative MRI data from the six-month analysis of the Phase II trial (PARA OA 008) evaluating a single six-week...
304 Views